Navigation Links
Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
Date:12/12/2007

MARIETTA, Ga., Dec. 12 /PRNewswire/ -- Solvay Pharmaceuticals, Inc., announced today that the company will continue to work closely with the U.S. Food and Drug Administration (FDA) to fully address the questions raised by members of the Cardio-Renal Advisory Committee in its meeting to consider tedisamil as a treatment for rapid conversion of recent onset atrial fibrillation to normal sinus rhythm (NSR).

The Committee voted against approval of tedisamil, at this time, requesting that Solvay Pharmaceuticals provides additional information to the Agency. While not binding, the Committee's recommendations will be considered by the FDA in its review of the New Drug Application (NDA) for tedisamil.

"Although we are disappointed with today's vote, we remain committed to working with the FDA to determine appropriate next steps in the review of this drug application," said Laurence Downey, M.D., President and CEO of Solvay Pharmaceuticals, Inc.

The New Drug Application (NDA) for tedisamil was filed with the FDA in December 2006. Following Solvay Pharmaceuticals' submission of additional clinical data amending the NDA for tedisamil, FDA extended the typical 10- month review period. Under this revised timeline, Solvay Pharmaceuticals anticipates action from the FDA on or before January 19, 2008.

About Atrial Fibrillation

Atrial fibrillation (AFib) is an abnormal heart rhythm, known as a cardiac arrhythmia, affecting the upper chambers of the heart (atria). In this condition, the electrical signals in the atria that are responsible for directing the activity of the lower chambers of the heart (ventricles) become unsynchronized, and the ventricles continue pumping, usually irregularly and rapidly. This fast, uncoordinated rhythm prevents the heart from efficiently pumping blood out to the body. Some heart conditions associated with AFib include hypertension, heart failure, and coronary artery disease.

AFib -- the most common clin
'/>"/>

SOURCE Solvay Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
4. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
5. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
6. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
7. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
8. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
9. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
10. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
11. FDA Advisory Committees Recommend Continued U.S. Marketing Authorization for Trasylol(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Pa. , July 10, 2014 ... Moberg Research,s (Moberg) medical device manufacturing facility. Rep. ... Moberg,s advanced neurological monitors facilitate cutting-edge research in ... Rep. Kennedy and mental health advocate, Garen ... organization dedicated to fostering fundamental changes that will ...
(Date:7/10/2014)... , July 10, 2014  Decision Resources Group ... infectious disease (ID) specialists are willing to prescribe ... (oritavancin) for use as OPAT, approximately two-thirds of ... agents to their hospital inpatients. However, our findings ... patients are initiated on OPAT following hospital discharge, ...
(Date:1/15/2014)... , Jan. 15, 2014 Sono-Tek Corporation (OTC BB: ... ended November 30, 2013, compared to sales of $2,202,000 for ... Once again, this quarter has also shown growth over the ... first quarter of this fiscal year. Markets that experienced sales ...
Breaking Medicine Technology:Representative Patrick Kennedy visits Moberg's medical device facility to discuss improvement in brain injury care 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3Sono-Tek Announces Third Quarter Results 2Sono-Tek Announces Third Quarter Results 3Sono-Tek Announces Third Quarter Results 4
... Inc. (Nasdaq: MSON ), a developer of minimally invasive ... the ablation of tumors and worldwide for other acute health ... year ended June 30, 2009. , The Company also reported ... payment of $3.5 million was received on April 7, 2009 ...
... , SAN MATEO, Calif., Oct. 1 Corthera Inc. ... (FDA) has granted Fast Track designation to relaxin, the ... failure (AHF). The Fast Track program facilitates the development ... treat serious or life-threatening conditions and that demonstrate the ...
Cached Medicine Technology:Misonix Reports Fourth Quarter and Fiscal Year 2009 Financial Results 2Misonix Reports Fourth Quarter and Fiscal Year 2009 Financial Results 3Misonix Reports Fourth Quarter and Fiscal Year 2009 Financial Results 4Misonix Reports Fourth Quarter and Fiscal Year 2009 Financial Results 5Misonix Reports Fourth Quarter and Fiscal Year 2009 Financial Results 6Misonix Reports Fourth Quarter and Fiscal Year 2009 Financial Results 7Misonix Reports Fourth Quarter and Fiscal Year 2009 Financial Results 8Misonix Reports Fourth Quarter and Fiscal Year 2009 Financial Results 9Misonix Reports Fourth Quarter and Fiscal Year 2009 Financial Results 10Corthera's Relaxin Receives FDA Fast Track Designation for the Treatment of Acute Heart Failure 2Corthera's Relaxin Receives FDA Fast Track Designation for the Treatment of Acute Heart Failure 3
(Date:7/13/2014)... July 13, 2014 Fuel additives are ... gasoline, diesel, jet fuel, kerosene, and so on, in ... responsible for reducing the corrosion effects caused by fuels ... added to any fuel, provide economies of scale in ... escalate the overall cost of the fuel products. , ...
(Date:7/13/2014)... July 13, 2014 MarketsandMarkets recently ... [3D Modeling; 3D Scanning; 3D rendering; Layout and ... Analysis (2013 - 2018)”, which analyzes and studies ... North America, Western Europe, Eastern Europe, Middle East ... also draws the competitive landscape of the 3D ...
(Date:7/13/2014)... HealthDay Reporter FRIDAY, July 11, ... for people with diabetes is being developed to measure sugar ... report. Scientists at Brown University in Providence, R.I., created ... uses light, metal and a special enzyme that changes color ... have to prick their fingers to draw blood to check ...
(Date:7/13/2014)... 2014 Athletes with a certain genetic ... concussions, according to research presented today at the American ... Meeting. The research marks the first of its kind ... known physical events that occur after a head injury. ... allele in the (GT)n genotype were four times more ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 Recently, ... retailer, has unveiled its new range of gorgeous ... current market, the demand for elegant Quinceanera outfits ... more beautiful items. All the company’s newly released ... trends. They are all elegant and vivid. ...
Breaking Medicine News(10 mins):Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 2Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 3Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 4Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 2Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 3Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 4Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 2Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 3Health News:Genetic Factors May Be Responsible for Slowing Concussion Recovery in Athletes 2Health News:2014QuinceaneraDresses.com Releases Its New Quinceanera Dresses 2
... and Crest/Oral-B Survey Unveiled at ... 2008 The American Dental,Association (ADA(R)), in collaboration with Crest(R) and ... care., Here is a sneak peek at the key ... of one,s mouth, teeth and gums is ...
... 2008/2009 survey of more than 5,500 benefit plans found 68.3 percent of ... increasing the employee portion of the premium. , ... Kansas City, KS ... containment and cost reduction measures to combat rising health care costs. The ...
... test to identify those most at risk from hair loss is now ... ... (PRWEB) October 17, 2008 -- A groundbreaking genetic test to identify those ... for both men and women. , , ,Currently only available at ...
... Year 2020, Food Companies Will Be Expected to Cede ... Oct. 16 Today,s consumers want to have a,greater ... the year,2020, consumers around the globe expect the way ... to a recent study of consumers in five,countries., ...
... Consumers, FALLS CHURCH, Va., Oct. 16 ... of digestive health issue (*see reference,below). The issue ... in,which prebiotics and probiotics could benefit them. For ... for prebiotics and,probiotics by working with a truly ...
... Oct. 16 Americans United for Life,(AUL) today filed ... Ohio,s regulation of the deadly abortion drug, RU-486., ... proven track,record of ruining and even ending women,s lives. ... of this drug. Ohio,s statute is a,step in the ...
Cached Medicine News:Health News:New National Public Opinion Survey Reveals Important Findings on Oral Health Care Perceptions 2Health News:New National Public Opinion Survey Reveals Important Findings on Oral Health Care Perceptions 3Health News:Employers' Methods for Containing and Reducing Costs Vary By Region 2Health News:Employers' Methods for Containing and Reducing Costs Vary By Region 3Health News:Breakthrough Baldness Genetic Test 2Health News:New Study Reveals Consumers Want Greater Say in Key Food Issues 2Health News:New Study Reveals Consumers Want Greater Say in Key Food Issues 3Health News:New Study Reveals Consumers Want Greater Say in Key Food Issues 4Health News:New Study Reveals Consumers Want Greater Say in Key Food Issues 5Health News:MyHealthGate, Inc. Joins With LiveActive Chewy Granola Bars to Raise Digestive Health Awareness 2Health News:Ohio's Regulation of RU-486 Clear and Constitutional, Should Be Upheld Argues AUL in Brief Filed Before Ohio Supreme Court 2
... Aplicare's Saturated Swabsticks are packaged ... Each 4 inch Swabstick is saturated ... solution. Each package is terminally sterilized, ... the patient. Povidone Iodine Scrub is ...
... 70% alcohol and 10% povidone iodine ... forming a barrier on the skin. ... for the povidone iodine, giving persistent ... with catheter related infections for up ...
... Aplicare's Saturated Swabsticks are ... single-use foil-laminated pouches. Each ... saturated with precisely the ... Each package is terminally ...
Triad Plus PVP-I Prep Solution has broad-spectrum germicidal action. Povidone Iodine Solution using an innovative one-piece screw cap, Triad Plus bottles are designed specifically to meet the needs o...
Medicine Products: